Prem Watsa
Fairfax Financial Holdings
Prem Watsa Xeris Pharmaceuticals Inc stake
total: 291
Fairfax Financial Holdings XERS trades
- Total transactions:
- 4
- New positions:
- 1
- Sold out:
- 1
- Added:
- 1
- Reduced:
- 1
- Held since:
- 2021 Q4
- Held for:
- 13 quarters
- Latest activity:
- 2025 Q1
According to 2026 Q2 report, Prem Watsa doesn't hold any Xeris Pharmaceuticals Inc (XERS) shares. To date, the estimated cost basis is nearly $2.84 for "buy" trades and estimated average "sell" price is $3.38. Fairfax Financial Holdings first purchased XERS in 2021 Q4, initially acquiring 151,395 shares. Since the initial investment in Xeris Pharmaceuticals Inc (XERS), Fairfax Financial Holdings has made 3 more transactions.
When did Prem Watsa sell Xeris Pharmaceuticals Inc (XERS)?
Prem Watsa sold off the entire Xeris Pharmaceuticals Inc (XERS) position in 2025 Q1.
When did Prem Watsa buy Xeris Pharmaceuticals Inc (XERS)?
Prem Watsa first invested in Xeris Pharmaceuticals Inc (XERS) in 2021 Q4 at the reported quarter-end price of $2.91 per share.
What's the cost basis of Fairfax Financial Holdings's XERS stake?
The estimated cost basis for Xeris Pharmaceuticals Inc (XERS) stake is around $2.84 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $2.84
- Weighted AVG sell price:
- $3.38
Prem Watsa's historical trades in Xeris Pharmaceuticals Inc
4 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q1
|
0.00%
|
0
|
$3.38
|
|
-100% (-139,687)
|
-0.03%
|
|
2024 Q4
|
0.03%
|
139,687
|
$3.38
|
$472,142
|
-18.28% (-31,250)
|
-0.01%
|
|
2024 Q2
|
0.03%
|
170,937
|
$2.24
|
$382,899
|
+12.91% (+19,542)
|
+0%
|
|
2021 Q4
|
0.01%
|
151,395
|
$2.91
|
$441,000
|
new
|
+0.01%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.